[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-artery-calcifications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-artery-calcifications":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100650509","intravascular-lithotripsy-versus-rotational-atherectomy-for-severe-coronary-artery-calcification-a-prospective-multicenter-non-inferiority-randomized-controlled-trial-100650509",false,"NCT07750964","Intravascular Lithotripsy Versus Rotational Atherectomy for Severe Coronary Artery Calcification: A Prospective, Multicenter, Non-inferiority Randomized Controlled Trial","LIRAC","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Target lesion with diameter stenosis ≥ 50% (visual estimation) associated with evidence of myocardial ischemia;\n3. Target lesion must be a de novo, in-situ severely calcified coronary lesion, where severe calcification is defined as: radiopacity visible prior to contrast injection and in the absence of cardiac pulsation, typically involving both sides of the vessel wall; and ≥270° circumferential calcification as evidenced by intravascular ultrasound (IVUS);\n4. Target vessel reference diameter between 2.5 and 4.0 mm, with successful guidewire traversal;\n5. A maximum of two non-target lesions requiring interventional treatment, which must be successfully treated prior to the target lesion;\n6. Patients presenting with evidence of symptomatic or asymptomatic myocardial ischemia, stable or unstable angina pectoris, or prior myocardial infarction;\n7. Signed written informed consent obtained.\n\nExclusion Criteria:\n\n1. Cardiogenic shock or hemodynamic instability;\n2. Chronic total occlusion (CTO);\n3. Requirement for intraprocedural mechanical circulatory support, such as intra-aortic balloon pump (IABP) or Impella device;\n4. Acute ST-segment elevation myocardial infarction (STEMI) occurring within 1 month prior to enrollment;\n5. Angiographically visible thrombus at the target lesion site;\n6. Left main ostial lesion with stenosis ≥ 50%;\n7. Left ventricular ejection fraction (LVEF) \\\u003C 40%;\n8. New-onset stroke or transient ischemic attack (TIA) within 90 days;\n9. Bypass graft lesion;\n10. Coronary artery dissection of type B or greater (NHLBI classification);\n11. Pregnant or lactating patients;\n12. Life expectancy \\\u003C 1 year;\n13. Active bleeding;\n14. Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73 m²;\n15. Presence of cognitive or psychiatric disorders, as confirmed by clinical diagnosis or investigator assessment;\n16. Illiteracy, semi-literacy, or any visual impairment, reading\u002Fwriting disability that prevents the patient from independently reading the patient information sheet and personally providing written informed consent without assistance.","ALL","18 Years",{"count":19,"type":20},190,"ESTIMATED","INTERVENTIONAL",[23],"NA","Severely calcified coronary lesions represent one of the major challenges in interventional cardiology. Severe coronary calcification increases the difficulty and complexity of percutaneous coronary intervention (PCI), impedes device delivery, and may even lead to device failure. Moreover, stent underexpansion further elevates the risks of cardiac death, myocardial infarction, target vessel revascularization, and in-stent thrombosis. Rotational atherectomy (RA) is an effective modality for treating severely calcified coronary lesions, as it adequately modifies calcific plaques, facilitates luminal enlargement, and improves device deliverability. However, RA fragments calcific plaques into microparticles that are subsequently cleared by the reticuloendothelial system in the distal microvasculature, potentially inducing microvascular dysfunction.\n\nIn recent years, intravascular lithotripsy (IVL) has emerged as an innovative calcium-modification technique in clinical practice. This technology employs acoustic pressure waves to selectively disrupt deep-seated calcific plaques, inducing fractures within the calcium while sparing the soft tissue of the vessel wall from substantial injury. IVL is performed with low-pressure balloon inflation (4-6 atm), which helps to minimize the risk of vascular injury; its mechanism of action does not produce macroscopic debris, theoretically obviating distal embolization and associated microcirculatory disturbances. Recently published prospective observational studies-the REPLICA-EPIC18 and BENELUX-IVL registries-have demonstrated that IVL is feasible and safe in \"real-world\" severely calcified lesions, effectively facilitating stent implantation.\n\nAlthough both RA and IVL are important tools for managing severe calcific lesions, there remains a paucity of high-level, head-to-head evidence directly comparing post-procedural minimal stent area between the two modalities. Clarifying this issue is of significant clinical importance for guiding clinicians in selecting optimal revascularization strategies tailored to distinct pathological characteristics and patient profiles, thereby improving procedural safety and patient outcomes. To this end, we plan to conduct a prospective, multicenter, randomized clinical trial (RCT) aimed at comparing the minimal stent area between intravascular lithotripsy and rotational atherectomy in patients with severely calcified lesions.",[26,27,28,29],"Coronary Artery Calcifications","Intravascular Lithotripsy","Rotational Atherectomy","Intravascular Ultrasound","NOT_YET_RECRUITING","2026-08-03",{"date":33,"type":34},"2026-08-06","ACTUAL",{"date":36,"type":20},"2026-10-01",{"date":38,"type":20},"2030-06-30",{"name":40,"class":41},"Second Affiliated Hospital, Zhejiang University, School of Medicine","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100645551","multicenter-cardiac-decision-impact-study-in-people-with-breast-cancer-100645551","NCT07703033","Multicenter Cardiac Decision Impact Study in People With Breast Cancer","ARTILLERY-CarDI, Early Detection of Non-communicable Disease Risk in People With Breast Cancer: Multicenter Cardiac Decision Impact Study","CarDI","Inclusion Criteria:\n\n* diagnosed with breast cancer or ductal carcinoma in situ\n* Planned for radiotherapy\n* From 35 years of age onwards\n\nExclusion Criteria:\n\n* Pregnancy\n* Breastfeeding","35 Years",{"count":52,"type":20},1000,[23],"Background:\n\nBreast cancer is the most common cancer in women, and advances in early detection and treatment have led to steadily improved survival rates. Today, nearly 80% of breast cancer survivors are over 50 years of age. With longer survival, comes a greater burden of chronic disease, particularly cardiovascular disease (CVD), which is more common in breast cancer survivors than in the general population. This elevated risk is driven by treatment-related effects, such as chemotherapy- and radiotherapy-induced cardiotoxicity, metabolic changes including (therapy-associated) weight gain, and shared lifestyle risk factors such as obesity and physical inactivity. In routine clinical care, approximately 65% of breast cancer patients undergo local radiotherapy (RT) and will receive a planning computed tomography (CT) scan. These scans, while intended for RT planning, also capture valuable information on coronary artery calcifications (CAC), a well-established marker risk factor of CVD risk.\n\nThe ARTILLERY-CarDI study is a multinational decision impact trial which will evaluate calculating CAC-based CVD risk (Agatston score) and communicating personalized, risk-based management recommendations to breast cancer patients.\n\nAims and outcomes:\n\nIn this study, CVD risk is estimated based on the manual CAC (Agatston) score using RT planning CT scans and a corresponding CVD risk-based recommendation is provided to breast cancer patients. The main aim of this study is to disclose this estimated CVD risk to treating physicians and patients and investigate how this risk affects:\n\n1. breast cancer treatment (retrospectively) and cardiovascular care (i.e., no further action, recommendation for lifestyle changes, referral to a cardiologist or general practitioner (GP)), and\n2. patients' satisfaction with their decision to receive their estimated CVD risk and the corresponding CVD risk-based management.\n\nSecondary aims are to evaluate whether the knowledge of estimated CVD risk and corresponding CVD-risk based management impacts patients' decisions regarding their lifestyle and habits, decisional conflict regarding lifestyle decision changes, patient reported outcomes (PROs) and changes in CVD risk factors and CVD treatment.\n\nMethods:\n\nARTILLERY-CarDI is a multinational, multicenter, prospective decision impact trial, designed as a within-subject trial in which participants serve as their own controls. A total of 1,000 patients with breast cancer will be enrolled over 1.5 years across five centers in four countries (the Netherlands with two participating centers, Germany, Portugal, and Denmark). Each participant will be followed for six months.\n\nThe intervention is the CVD risk estimation based on the CAC (Agatston) score using RT planning CT scans, and the subsequent disclosure of the estimated CVD risk and corresponding CVD risk-based management to the patient using the ARTILLERY manual. The CAC (Agatston) score will be measured after the RT planning CT scan is made, which is usually one or two weeks before the start of RT. The Agatston score is a validated method for CVD risk assessment using the amount of CAC. CVD risk is categorized in 5 groups with an Agatston score of 0, 1-10, 11-100, 101-400, and \\>400. In the current trial, endpoints will be analyzed according to low, moderate, and high-CVD-risk groups corresponding to score ranges 0-10, 11-100, and \\>100, respectively.\n\nFollowing a study-specific manual , eligible patients will be referred to a cardiologist or GP if a previously unknown moderate to high risk of CVD according to CAC is determined (Agatston score \\>10). Thereafter, these patients will be treated accordingly as part of standard care. We expect that the timely measurement of estimated CVD risk by the amount of CAC on a planning CT scan and the disclosure of CVD risk-based management is beneficial for patients. The CVD risk measurement will lead to the identification of breast cancer patients with a previously unknown moderate to high estimated CVD risk and possibly undertreated cardiac conditions. The disclosure of CVD risk-based management is intended to empower patients to manage their own physical health and well-being. Also, we expect that the CVD risk measurement and CVD risk-based management will create more awareness among doctors and citizens about CVD risk in breast cancer patients. A potential side-effect of CAC- based CVD risk measurement and disclosure of CVD risk-based management is that, some patients may experience increased anxiety leading to dissatisfaction or regret about their decision to participate. The Satisfaction with Decision (SWD) questionnaire will be used to measure patients' satisfaction about their decision as one of the primary outcomes and the level of anxiety by the Hospital Anxiety and Depression Scale, at baseline, at one month and at six months after the intervention.",[56,57,26],"Breast Cancer","Cardiovascular (CV) Risk",[59,60,61,62,63],"Radiotherapy planning CT scans","Decision impact trial","patient reported outcomes","decisional conflict","satisfaction with decision","RECRUITING","2026-07-08",{"date":67,"type":34},"2026-07-14",{"date":69,"type":34},"2026-04-20",{"date":71,"type":20},"2028-05-01",{"name":73,"class":41},"UMC Utrecht",5]